Loading...
Loading...
ATNX| Name | Value |
|---|---|
| Revenues | 31.5M |
| Cost of Revenue | 23.1M |
| Gross Profit | 8.4M |
| Operating Expense | 30.3M |
| Operating I/L | -21.8M |
| Other Income/Expense | -2.2M |
| Interest Income | 0.0M |
| Pretax | -24.1M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -24.0M |
Athenex, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of cancer treatment drugs. The company operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Its product candidates include Oral paclitaxel and encequidar for metastatic breast cancer, as well as Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. Athenex is also developing autologous and allogeneic products for various cancer treatments, along with TCR-T cell therapy for solid tumors. Additionally, the company is working on dual absorption enhancers and a portfolio of TCRs targeting hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.
